Do Allergies Increase Cancer Risk? New Meta-Analysis Finds Weak but Statistically Significant Link

A comprehensive meta-analysis published in Scientific Reports indicates a modest statistical association between allergic diseases and an increased risk of cancer, with an odds ratio (OR) of 1.07. While the overall link is weak, the study highlights a more pronounced correlation specifically with asthma, though researchers emphasize these findings show association, not direct causation.

Asthma Shows the Strongest Correlation With Cancer Incidence

Among various allergic conditions, asthma emerged as the only allergy with a statistically significant association with cancer incidence. According to the study, the odds ratio for asthma is 1.18 (95% CI: 1.10–1.28). This signal is more visible than those for other atopic conditions, though it remains moderate in scale.

Medical researchers suggest several factors could explain this link. Chronic inflammation associated with long-term asthma may play a role, or the effects could be influenced by the severity of the disease and the long-term use of specific medications, such as corticosteroids. In contrast, the data for hay fever and atopic dermatitis did not show a clear or consistent association with overall cancer risk.

Cancer Types Linked to Allergic Backgrounds

The analysis found that the relationship between allergies and cancer varies significantly depending on the organ system involved. The study reported observed associations with the following specific cancers:

• Lung cancer
• Kidney, testicular, and thyroid cancers

Conversely, the data revealed an inverse relationship for certain types of malignancies. Specifically, the researchers noted a negative association with colorectal and uterine cancers. This contrast suggests that allergic responses do not uniformly increase cancer risk across all tissues, but rather interact with different biological environments in complex ways.

Geographic Variations in Risk Data

The strength of the association fluctuates based on the region where the cohorts were studied. The most significant signal appeared in the Western Pacific region, where the odds ratio reached 1.65 (95% CI: 1.22–2.21). In contrast, data from the Americas and Europe did not reach the threshold of statistical significance.

These disparities likely stem from differences in environmental exposures, such as pollution and diet, as well as variations in genetic profiles and regional diagnostic standards. The researchers noted that the higher estimate in the Western Pacific was based on a limited number of studies, meaning more data is required to confirm this regional trend.

Study Methodology and Limitations

The research team analyzed 28 cohort and case-control studies published between 1999 and 2024. The data spanned multiple countries, including the United States, United Kingdom, Sweden, Denmark, Finland, Australia, Taiwan, and South Korea. By focusing on cohorts, the researchers aimed to ensure that the allergy diagnosis preceded the cancer diagnosis.

Despite the breadth of the data, the authors identified significant heterogeneity between the included studies. Variations in how “allergy” and “cancer” were defined across different healthcare systems introduce uncertainty. Additionally, while an Egger test did not find a statistically clear small-study effect, the researchers noted that publication bias remains a possibility.

Clinical Implications for Patients

For individuals with allergies, these findings do not warrant a change in medical treatment or the adoption of aggressive cancer screening based solely on an allergy diagnosis. The overall risk increase is small and inconsistent across different types of allergies and cancers.

The study serves primarily as a roadmap for future research. It suggests that scientists should focus on whether severe asthma differs from mild asthma in terms of risk and whether the primary driver is the underlying immune inflammation or the pharmacological interventions used to treat the allergy.